RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma (HCC)
Includes cost sharing for development in third-line CRC and second-line HCC
https://finance.yahoo.com/news/replimune-enters-clinical-collaboration-agreement-113000034.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.